[Molecular remission of chronic myeloid leukaemia in a patient with hepatitis and a second kidney transplant].
Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by clonal expansion of cells in the myeloid line, expressing the BCR-ABL fusion protein responsible for the oncogenic effect of CML. The current frontline therapy in CML is the BCR-ABL tyrosine kinase inhibitor, Imatinib. Although this drug has been shown to improve survival in CML patients, its role in the context of a transplant setting has not been widely described in the literature. We report on the long term molecular remission of CML in a 55 year old man with a second renal transplant who is hepatitis C virus positive, and has associated cardiovascular and immunological risk factors.
Castillo-Rama
M
M
Hospital 12 de Octubre, Madrid.
Grande
C
C
Martínez-Sanchez
P
P
Olavarria
E
E
Marín
D
D
Paz-Artal
E
E
Andrés
A
A
Morales
J M
JM
D006526:Hepatitis C / Q000150:complications; D006801:Humans; D016030:Kidney Transplantation; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D012086:Reoperation